{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:03:42Z","timestamp":1793142222317,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T00:00:00Z","timestamp":1606521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.heliyon.2020.e05641","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T11:36:36Z","timestamp":1606995396000},"page":"e05641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-9596","authenticated-orcid":false,"given":"Radwan","family":"Alnajjar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Kandeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A.","family":"Al-Karmalawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2020.e05641_bib1","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Department of virology , biological and pathological center , centre hospitalier","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.heliyon.2020.e05641_bib2","series-title":"Coronavirus Disease (COVID-19) Pandemic","author":"WHO","year":"2020"},{"issue":"1","key":"10.1016\/j.heliyon.2020.e05641_bib3","first-page":"35","article-title":"The rise of new coronavirus infection-(COVID-19): a recent update","volume":"4","author":"Mali","year":"2020","journal-title":"Eur. J. Med. Oncol."},{"issue":"6485","key":"10.1016\/j.heliyon.2020.e05641_bib4","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science (80- )"},{"issue":"6489","key":"10.1016\/j.heliyon.2020.e05641_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science (80- )"},{"issue":"13","key":"10.1016\/j.heliyon.2020.e05641_bib6","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","article-title":"Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra \u03b1-helical domain","volume":"21","author":"Anand","year":"2002","journal-title":"EMBO J."},{"issue":"23","key":"10.1016\/j.heliyon.2020.e05641_bib7","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2020.e05641_bib8","first-page":"1","article-title":"Clinical Implications of Basic Research How to Discover","author":"Parks","year":"2020","journal-title":"Antivir. Drugs Quickl."},{"issue":"11","key":"10.1016\/j.heliyon.2020.e05641_bib9","first-page":"914\u2014918","article-title":"Therapeutic switching: a new strategic approach to enhance R&D productivity","volume":"8","author":"Cavalla","year":"2005","journal-title":"Idrugs"},{"issue":"4","key":"10.1016\/j.heliyon.2020.e05641_bib10","first-page":"405","article-title":"The Drug Repurposing Hub: a next-generation drug library and information resource","volume":"23","author":"Corsello","year":"2017","journal-title":"Inf. Res."},{"key":"10.1016\/j.heliyon.2020.e05641_bib11","series-title":"Tanshinone IIA Synergistically Enhances the Antitumor Activity of Doxorubicin by Interfering with the PI3K\/AKT\/mTOR Pathway and Inhibition of Topoisomerase II\u00a0: in Vitro and Molecular Docking Studies \u2020","author":"Ghanem","year":"2020"},{"key":"10.1016\/j.heliyon.2020.e05641_bib12","series-title":"Empagli Fl Ozin and Doxorubicin Synergistically Inhibit the Survival of Triple-Negative Breast Cancer Cells via Interfering with the mTOR Pathway and Inhibition of Calmodulin\u00a0: in Vitro and Molecular Docking Studies","first-page":"1","author":"Eliaa","year":"2020"},{"issue":"18","key":"10.1016\/j.heliyon.2020.e05641_bib13","article-title":"Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review","volume":"323","author":"Sanders","year":"2020","journal-title":"JAMA, J. Am. Med. Assoc."},{"key":"10.1016\/j.heliyon.2020.e05641_bib14","series-title":"Molecular Docking Reveals the Potential of Cleome Amblyocarpa Isolated Compounds to Inhibit COVID-19 Virus Main Protease \u2020","author":"Zaki","year":"2020"},{"issue":"April","key":"10.1016\/j.heliyon.2020.e05641_bib15","first-page":"3","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antivir. Res."},{"issue":"7","key":"10.1016\/j.heliyon.2020.e05641_bib16","article-title":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?","volume":"9","author":"Sommerstein","year":"2020","journal-title":"J.\u00a0Am. Heart Assoc."},{"issue":"5","key":"10.1016\/j.heliyon.2020.e05641_bib17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1473-3099(20)30120-1","article-title":"An interactive web-based dashboard to track COVID-19 in real time","volume":"20","author":"Dong","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2020.e05641_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ijcard.2020.03.063","article-title":"The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease","volume":"309","author":"Tan","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.heliyon.2020.e05641_bib19","first-page":"1","article-title":"COVID-19 and renin angiotensin blockers: current evidence and recommendations","author":"Messerli","year":"2020","journal-title":"Circulation"},{"issue":"April","key":"10.1016\/j.heliyon.2020.e05641_bib20","first-page":"1","article-title":"Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19","author":"Rothlin","year":"2020","journal-title":"Drug Dev. Res."},{"issue":"12","key":"10.1016\/j.heliyon.2020.e05641_bib21","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang","year":"2020","journal-title":"Circ. Res."},{"issue":"10238","key":"10.1016\/j.heliyon.2020.e05641_bib22","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"Use of renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2020.e05641_bib23","series-title":"Molecular Operating Environment (MOE)","author":"Inc. CCG","year":"2016"},{"key":"10.1016\/j.heliyon.2020.e05641_bib24","series-title":"Release S and Others. 3: Desmond Molecular Dynamics System","year":"2017"},{"key":"10.1016\/j.heliyon.2020.e05641_bib25","article-title":"Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor","author":"Ahmed","year":"2020","journal-title":"New J. Chem."},{"key":"10.1016\/j.heliyon.2020.e05641_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from COVID-19 virus and discovery of its inhibitors","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.heliyon.2020.e05641_bib27","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jmb.2008.11.010","article-title":"RosettaLigand docking with full ligand and receptor flexibility","volume":"385","author":"Davis","year":"2009","journal-title":"J.\u00a0Mol. Biol."},{"issue":"7","key":"10.1016\/j.heliyon.2020.e05641_bib28","first-page":"845","article-title":"The performance of current methods in ligand-protein docking","volume":"83","author":"McConkey","year":"2002","journal-title":"Curr. Sci."},{"key":"10.1016\/j.heliyon.2020.e05641_bib29","series-title":"Molecular Modelling of Mebendazole Polymorphs as a Potential Colchicine Binding Site Inhibitor","author":"Al-karmalawy","year":"2020"},{"key":"10.1016\/j.heliyon.2020.e05641_bib30","series-title":"OPLS3\u00a0: A Force Field Providing Broad Coverage of Drug-like Small Molecules and Proteins","author":"Harder","year":"2016"},{"key":"10.1016\/j.heliyon.2020.e05641_bib31","first-page":"1902","article-title":"Simulation of Activation Free Energies in Molecular Systems I","volume":"1921","author":"Neria","year":"1996"},{"key":"10.1016\/j.heliyon.2020.e05641_bib32","series-title":"Comparison of Simple Potential Functions for Simulating Liquid Water Comparison of Simple Potential Functions for Simulating Liquid Water","first-page":"926","author":"Jorgensen","year":"1983"},{"key":"10.1016\/j.heliyon.2020.e05641_bib33","series-title":"4. Desmond Molecular Dynamics System, DE Shaw Research. Maest Interoperability Tools","author":"Release","year":"2016"},{"issue":"1992","key":"10.1016\/j.heliyon.2020.e05641_bib34","article-title":"Nos\u00e9 \u2013 hoover chains: the canonical ensemble via continuous dynamics Nose-Hoover chains: the canonical ensemble via continuous dynamics","volume":"2635","author":"Martyna","year":"2011","journal-title":"J.\u00a0Chem. Phys."},{"issue":"September","key":"10.1016\/j.heliyon.2020.e05641_bib35","article-title":"Constant pressure molecular dynamics algorithms","volume":"6323","author":"Martyna","year":"1994","journal-title":"J.\u00a0Chem. Phys."},{"key":"10.1016\/j.heliyon.2020.e05641_bib36","first-page":"129628","article-title":"Bicyclo[1.1.1]Pentane as phenyl substituent in atorvastatin drug to improve physicochemical properties: drug-likeness, DFT, pharmacokinetics, docking, and molecular dynamic simulation","author":"Alnajjar","year":"2020","journal-title":"J.\u00a0Mol. Struct."},{"key":"10.1016\/j.heliyon.2020.e05641_bib37","first-page":"29","article-title":"Research article of the essential oil of Nepeta Deflersiana Schweinf growing in KSA","volume":"7","author":"Of","year":"2016"},{"key":"10.1016\/j.heliyon.2020.e05641_bib38","first-page":"55","article-title":"Rapid Colorimetric Assay for Cellular Growth and Survival\u00a0: Application to Proliferation and Cytotoxicity Assays","volume":"65","author":"Mosmann","year":"1983"},{"key":"10.1016\/j.heliyon.2020.e05641_bib39","series-title":"Crystal Violet Assay for Determining Viability of Cultured Cells","first-page":"343","author":"Feoktistova","year":"2016"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020324841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844020324841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T08:59:27Z","timestamp":1770800367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844020324841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2405844020324841"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e05641","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular docking, molecular dynamics, and in vitro studies reveal the potential of angiotensin II receptor blockers to inhibit the COVID-19 main protease","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2020.e05641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e05641"}}